Home > News

 

 

ARCHIVE NEWS
Happiness&Wellbeing: Maria Paola Chiesi at the Vatican workshop
29 May 2020
Protalix BioTherapeutics and Chiesi Global Rare Diseases Announce Submission of Biologics License Application to U.S. Food and Drug Administration for Pegunigalsidase Alfa for the Treatment of Fabry Disease
28 May 2020
Chiesi Group and Apotex Inc. finalize agreement for acquisition of Ferriprox® (deferiprone)
13 January 2020
Chiesi Group Announces Closing of Licensing Transaction with Santhera for an orphan drug in LHON
02 August 2019
Chiesi Group signs an Option Agreement with Inhibrx for Development and Commercialization of INBRX-101 (AAT-Fc)
30 May 2019
Chiesi Group Enters into License Agreement with Santhera for a treatment for LHON
23 May 2019
Chiesi: “imprese per innovazione” award, Industry 4.0 and Sustainability Special Mentions
08 February 2019
Chiesi enters in an exclusive global license agreement with TiumBio to develop innovative molecules for respiratory diseases
09 January 2019
StartUp Health raises 31 million dollars from the Chiesi Group and a prominent group of other large pharmaceuticals companies and healthcare organizations
02 October 2018
Chiesi signs a deal with StartUp Health: first investment in the digital area
05 June 2018
© 2025 CHIESI Farmaceutici S.p.A.
VAT IT 01513360345
Company's Capital: Euro 75.000.000
Companies Register Office - Parma N.15739
REA: 159271

PHARMACOVIGILANCE

TO REPORT ADVERSE DRUG EVENTS/REACTIONS PLEASE CLICK HERE


follow us on: